

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-12. (Canceled)

13. (Currently Amended) A monoclonal antibody that competes with a monoclonal antibody MAb 763-15-5 (~~ATCC PTA-1079~~) for specific binding to the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2, and 2C9*3, wherein the MAb 763-15-5 and that specifically inhibits 2C9*1, 2C9*2, and 2C9*3 catalyzed metabolism of phenanthrene by at least 50% and 2C9*2 catalyzed metabolism of phenanthrene by at least 50%, wherein binding between the monoclonal antibody MAb 763-15-5 and the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2, and 2C9*3 is detectable by an enzyme-linked immunosorbent assay, and wherein MAb 763-15-5 is produced by the hybridoma cell line deposited as ATCC PTA-1079.

14. (Currently Amended) The monoclonal antibody of claim 13 that lacks specific binding to each of human cytochromes P450 1A1, 1A2, 2A6, 2B6, ~~2C9~~, 2C18, 2C19, 2D6, 2E1, 3A4, and 3A5.

15. (Currently Amended) The monoclonal antibody of claim 13 that ~~specifically~~ inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9*2 by at least 90%.

16-17. (Canceled)

18. (Previously Presented) The monoclonal antibody of claim 13 that is a Fab fragment.
19. (Previously Presented) The monoclonal antibody of claim 13 that is a mouse antibody.
20. (Previously Presented) A cell line producing the monoclonal antibody of claim 13.
21. (Original) The cell line of claim 20 that is a eucaryotic cell line.
22. (Previously Presented) The cell line of claim 20 that is a procaryotic cell line.
23. (Canceled)
24. (Previously Presented) The monoclonal antibody of claim 13, wherein the light chain variable domain comprises the three CDR regions from the light chain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079), and the heavy chain variable domain comprises the three CDR regions from the heavy chain of the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).
25. (Currently Amended) The monoclonal antibody of claim 13 that ~~specifically~~ inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic ~~variant~~ variants 2C9*1 and 2C9*3 by at least 70% and inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9*2 by at least 70%.

26. (Currently Amended) The monoclonal antibody of claim 13 that ~~specifically~~ inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 2C18 by 30%.

27-73. (Canceled)

74. (Previously Presented) The monoclonal antibody of claim 13, wherein the monoclonal antibody comprises the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

75. (New) A monoclonal antibody MAb 763-15-5 which is produced by the hybridoma cell line deposited as ATCC PTA-1079, wherein the monoclonal antibody MAb 763-15-5 specifically binds to the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2 and 2C9*3, and binding between the monoclonal antibody MAb 763-15-5 and the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2, and 2C9*3 is detectable by an enzyme-linked immunosorbent assay.

76. (New) A monoclonal antibody that competes with the monoclonal antibody MAb 763-15-5 of claim 75 for specific binding to the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2 and 2C9*3.

77. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9 catalyzed metabolism of phenanthrene by at least 50%.

78. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C18 catalyzed metabolism of phenanthrene by at least 30%.

79. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C18 catalyzed metabolism of phenanthrene by at least 30%.

80. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9 catalyzed metabolism of diclofenac by at least 50%.

81. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9*1 catalyzed metabolism of phenanthrene by at least 50%, and inhibits 2C9*2 catalyzed metabolism of phenanthrene by at least 50%.

82. (New) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9*1 catalyzed metabolism of diclofenac by at least 50%, inhibits 2C9*2 catalyzed metabolism of diclofenac by at least 50%, and inhibits 2C9*1 catalyzed metabolism of diclofenac by at least 50%.